The biochemical womb of schizophrenia: A review

Indian Journal of Clinical Biochemistry

Volumn 23, Issue 4, 2008, Pages 307-327

  Gaur, N ^a   Gautam, Shiv ^b   Gaur, M ^b   Sharma, P ^b   Dadheech, G ^a   Mishra, S ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^b SMS MEDICAL COLLEGE   (India)

Author keywords

Biochemical markers; Neurobiology; Schizophrenia

Indexed keywords

4 AMINOBUTYRIC ACID; ANDROSTERONE; CALCIUM; CERULOPLASMIN; CHOLECYSTOKININ; DOPAMINE; DOPAMINE RECEPTOR; GAMMA INTERFERON; GLUTAMIC ACID; GLYCINE; HOMOCYSTEINE; HOMOVANILLIC ACID; HYDROCORTISONE; INTERLEUKIN 2; INTERLEUKIN 6; N ACETYLASPARTIC ACID; N ACETYLASPARTYLGLUTAMIC ACID; NEUROTENSIN; NEUROTRANSMITTER; PRASTERONE; PRASTERONE SULFATE; PREGNENOLONE; PREGNENOLONE SULFATE; PROGESTERONE; SERINE; SEROTONIN; SOMATOSTATIN; TESTOSTERONE; TUMOR NECROSIS FACTOR ALPHA;

ADRENERGIC SYSTEM; AUTOIMMUNITY; CALCIUM SIGNALING; CHOLINERGIC SYSTEM; HUMAN; HYPERACTIVITY; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNOCOMPETENCE; NEUROCHEMISTRY; NEUROTRANSMISSION; PATHOPHYSIOLOGY; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; THEORY;

EID: 57149088901     PISSN: 09701915     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12291-008-0071-x     Document Type: Review

References (225)

1. Jablensky A, Sartorius N, Ernberg G, Anker M, Korten A, Cooper JE, Day R, Bertelsen A. Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study. Psychol Med Monogr Suppl 1992;20:1-97.
2. Rice DP. The economic impact of schizophrenia. J Clin Psychiatry. 1999;60 Suppl 1:4-6; discussion 28-30.
3. Lewis DA, Lieberman JA. Catching up on schizophrenia: natural history and neurobiology. Neuron 2000;28:325-34.
4. Andreasen NC. Schizophrenia: The fundamental questions. Brain Res Brain Res Rev 2000;31:106-12.
5. Miyamoto S, LaMantia AS, Duncan GE, Sullivan P, Gilmore JH, Lieberman JA. Recent advances in the neurobiology of schizophrenia. Mol Interv 2003;3(1):27-39.
6. Nudmamud-Thanoi S. Neurochemical abnormalities in schizophrenia. J Naresuan Univ 2005;13:61-72.
7. Guillin O, Laruelle M. Neurobiology of Dopamine in Schizophrenia. Cellscience Reviews 2005;2:79-107.
8. Snyder SH, Banerjee SP, Yamamura HI, Greenberg D. Drugs, neurotransmitters, and schizophrenia. Science 1974;184:1243-53.
9. Carlsson A. The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacol 1988;1:179-86.
10. Seeman P, Lee T. Antipsychotic drugs: Direct correlation between clinical potency and presynaptic action on dopamine neutrons. Science 1975;188:1217-19.
11. Weinberger DR. Implications of the normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 1987;44:660-69.
12. Duncan GE, Sheitman BB, Lieberman JA. An integrated view of pathophysiological models of schizophrenia. Brain Res Brain Res Rev 1999;29:250-64.
13. Lembreghts M, Ansseau M. Biological markers in schizophrenia. Encephale 1993;19:501-23.
14. Reynolds GP, Czudek C. New approaches to the drug treatment of schizophrenia. Adv Pharmacol 1995;32:461-503.
15. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 1992;49:538-44.
16. Bacopoulos NG, Hattox SE, Roth RH. 3,4-dihydroxyphenylacetic acid and homovanillic acid in rat plasma: possible indicators of central dopaminergic activity. Eur J Pharmacol 1979;56:225-36.
17. Lambert GW, Eisenhofer G, Jennings GL, Esler MD. Regional homovanillic acid production in humans. Life Sci 1993;53:63-75.
18. Maas JW, Contreras SA, Miller AL, Berman N, Bowden CL, Javors MA, Seleshi E, Weintraub S. Studies of catecholamine metabolism in schizophrenia/psychosis- I. Neurospsychopharmacol 1993;8:97-109.
19. Mazure CM, Nelson JC, Jatlow PI, Bowers MB. Plasma free homovanillic acid (HVA) as a predictor of clinical response in acute psychosis. Biol Psychiatry 1991;30:475-82.
20. Sharma RP, Javaid JI, Janicak PG, Comaty J, Davis JM. Plasma and CSF HVA before and after pharmacological treatment. Psychiatr Res 1989;28:97-104.
21. Soares JC, Innis RB. Neurochemical brain imaging investigations of schizophrenia. Biol Psychiatry 1999;46:600-15.
22. Amin F, Davidson M, Kahn RS, Schmeidler J, Stern R, Knott PJ, Apter S. Assessment of the central dopaminergic index of plasma HVA in schizophrenia. Schizophr Bull 1995;21:53-66.
23. Kelley ME, Yao JK, van Kammen DP. Plasma catecholamine metabolites as markers for psychosis and antipsychotic response in schizophrenia. Neuropsychopharmacol 1999;20:603-11.
24. 2 dopamine receptors in drug-naive schizophrenics. Science 1986;234:1558-63.
25. 11 C]N -methylspiperone. Psychiatry Res 1995;61:67-83.
26. Angst J. Psychoses in disulfiram (anatabus) treatment: review of literature and etiology. Schweiz Med Wochenschr 1956;86(46):1304-6.
27. Laruelle M, Abi-Dargham A, Gil R, Kegeles L, Innis RB. Increased dopamine transmission in schizophrenia: relationship to illness phases. Biol Psychiatry 1999;46:56-72.
28. Laruelle M. The role of endogenous sensitization in the pathophysiology of schizophrenia: implications from recent brain imaging studies. Brain Res Brain Res Rev 2000;31:371-84.
29. Tamminga CA, Lahti RA, Lahti AC, Carlsson A. Partial dopamine agonists in the treatment of psychotic illness. Current Issues in the Psychopharmacology of Schizophrenia, Breier A, Tran PV, Herrera JM, Tollefson GD, Bymaster FP, Eds 2001:279-288. Lippincott, Williams & Wilkins Healthcare, Philadelphia.
30. Carlsson A, Waters N, Waters S, Carlsson ML. Network interactions in schizophrenia: therapeutic implications. Brain Res Brain Res Rev 2000;31: 342-9.
31. Lawler CP, Prioleau C, Lewis MM, Mak C, Jiang D, Schetz JA, Gonzalez AM, Sibley DR, Mailman RB. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacol 1999;20:612-27.
32. Okubo Y, Suhara T, Suzuki K, Kobayashi K, Inoue O, Terasaki O, Someya Y, Sassa T, Sudo Y, Matsushima E, Iyo M, Tateno Y, Toru M. Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature 1997;385:634-6.
33. 3 receptors and use of antipsychotics in patients with schizophrenia: a postmortem study. Arch Gen Psychiatry 1997;54:225-32.
34. 4 receptors elevated in schizophrenia. Nature 1993;365:441-45.
35. Harrison PJ. The neuropathology of schizophrenia: a critical review of the data and their interpretation. Brain 1999;122:593-624.
36. Weinberger DR, Egan MF, Bertolino A, Callicott JH, Mattay VS, Lipska BK, Berman KF, Goldberg TE. Prefrontal neurons and the genetics of schizophrenia. Biol Psychiatry 2001;50:825-44.
37. Liljequist R, Haapalinna A, Ahlander M, Li YH, Mannisto PT. Catechol-O-methyltransferase inhibitor tolcapone has minor influence on performance in experimental memory models in rats. Behav Brain Res 1997;82:195-202.
38. Gasparini M, Fabrizio E, Bonifati V, Meco G. Cognitive improvement during tolcapone treatment in Parkinson's disease. J Neural Transm 1997;104:887-94.
39. Gogos JA, Morgan M, Luine V, Santha M, Ogawa S, Pfaff D, Karayiorgou M. Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior. Proc Natl Acad Sci USA 1998;95:9991-96.
40. Egan MF, Goldberg TE, Kolachana BS, Callicott JH, Mazzanti CM, Straub RE, Goldman D, Weinberger DR. Effect of COMT Val108/158Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci USA 2001;98:6917-22.
41. Williams HJ, Glaser B, Williams NM, Norton N, Zammit S, Macgregor S, Kirov GK, Owen MJ, O'Donovan MC. No association between schizophrenia and polymorphisms in COMT in two large samples. Am J Psychiatry 2005;162:1736-38.
42. Williams HJ, Owen MJ, O'Donovan MC. Is COMT a Susceptibility Gene for Schizophrenia? Schizophr Bull 2007;33:635-41.
43. Lieberman JA, Mailman RB, Duncan G, Sikich L, Chakos M, Nichols DE, Kraus JE. Serotonergic basis of antipsychotic drug effects in schizophrenia. Biol Psychiatry 1998;44:1099-17.
44. 1 recognition sites. J Recept Res 1988;8:59-81.
45. 2a receptors. Br J Psychiatry Suppl 1999;38:12-22.
46. Kahn RS, Siever L, Davidson M, Greenwald C, Moore C. Haloperidol and clozapine treatment and their effect on m-chlorophenylpiperazine-mediated responses in schizophrenia: implications for the mechanism of action of clozapine. Psychopharmacol 1993;112:S90-S94.
47. Lerer B, Ran A, Blacker M, Silver H, Weller MP, Drummer D, Ebstein B, Calev A. Neuroendocrine responses in chronic schizophrenia. Evidence for a serotonergic dysfunction. Schizophr Res 1988;1:405-10.
48. Maes M, Meltzer HY. Effects of meta-chlorophenylpiperazine on neuroendocrine and behavioral responses in male schizpherenic patients and normal volunteers. Psychiatry Res 1996;64:147-69.
49. Marshall BD Jr, Glynn SM, Midha KK, Hubbard JW, Bowen LL, Banzett L, Mintz J, Liberman RP. Adverse effects of fenfluramine in treatment refractory schizophrenia. J Clin Psychopharmacol 1989;9:110-15.
50. Bryan L. Roth, Herbert Y. Meltzer. The Role of Serotonin in schizophrenia. 2000. http://www.acnp.org/g4/GN401000117/CH115.html
51. Govitrapong P, Chagkutip J, Turakitwanakan W, Srikiatkhachorn A. Platelet 5-HT(2A) receptors in schizophrenic patients with and without neuroleptic treatment. Psychiatry Res 2000;96:41-50.
52. Govitrapong P, Mukda S, Turakitwanakan W, Dumrongphol H, Chindaduangratn C, Sanvarinda Y. Platelet serotonin transporter in schizophrenic patients with and without neuroleptic treatment. Neurochem Int 2002;41:209-16.
53. Meltzer HY, Li Z, Kaneda Y, Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:1159-72.
54. Meltzer HY. The Role of Serotonin in Antipsychotic Drug Action. Neuropsychopharmacol 1999;21:106S-115S.
55. 2 agonists or antagonistss? Neuropsychopharmacol 1990;3:509-17.
56. Meltzer HY, Kennedy J, Dai J, Parsa M, Riley D. Plasma clozapine levels and the treatment of L-DOPA-induced psychosis in Parkinson's disease: a high potency effect of clozapine. Neuropsychopharmacol 1995;12:39-45.
57. 2 receptors in chronic schizophrenics. Biol Psychiatry 1986;21:1407-14.
58. 2) receptor binding in the frontal cortex of schizophrenic patients. J Neural Transm 1991;85:19-29.
59. Laruelle M, Abi-Dargham A, Casanova MF, Toti R, Weinberger DR, Kleinman JE. Selective abnormalities of prefrontal serotonergic receptors in schizophrenia. A postmortem study. Arch Gen Psychiatry 1993;50:810-18.
60. Bleich A., Brown SL, Kahn R., van Praag HM. The role of serotonin in schizophrenia. Schizophr Bull 1988;14:297-315.
61. 2A receptors in prefrontal and temporal cortices of brains from patients with chronic schizophrenia. Life Sci 1991;48:355-63.
62. 1A receptors in ventral prefrontal cortex in schizophrenia. Biol Psychiatry 1996;39:919-28.
63. Abi-Dargham A, Laruell M, Aghajanian GK, Charney D, Krystal J. The role of serotonin in the pathophysiology and treatment of schizophrenia. Neuropsychiatr Clin Neurosci 1997;9:1-17.
64. Ferre S, Cortes R, Artigas F. Dopaminergic regulation of the serotonergic raphe-striatal pathway: microdialysis studies in freely moving rats. J Neurosci 1994;14:4839-46.
65. Hicks PB. The effect of serotonergic agents on haloperidol-induced catalepsy. Life Sci 1990;47:1609-15.
66. Kelland MD, Freeman AS, Chiodo LA. Serotonergic afferent regulation of the basic physiology and pharmacological responsiveness of nigrostriatal dopamine neurons. J Pharmacol Exp Ther 1990;253:803-11.
67. 2 dopamine receptor binding in the basal ganglia of antipsychotic-free schizophrenic patients. Br J Psychiatry 1994;164:16-26.
68. 2 receptor and alpha 1-andrenoceptor antagonism. J Clin Psychopharmacol 1995;15:11S-18S.
69. Choi DW, Koh JY, Peters S. Pharmacology of glutamate neurotoxicity in cortical cell culture: attenuation by NMDA antagonists. J Neurosci 1988;8:185-96.
70. Court JA, Perry EK, Johnson M, Piggott MA, Kerwin JA, Perry RH, Ince PG. Regional patterns of cholinergic and glutamate activity in the developing and aging human brain. Brain Res Dev Brain Res 1993;74:73-82.
71. Coyle JT, Puttfarcken P. Oxidative stress, glutamate and neurodegenerative disorders. Science 1993;262:689-95.
72. Egan MF, Weinberger DR. Neurobiology of schizophrenia. Curr Opin Neurobiol 1997;7:701-07.
73. Goff DC, Wine L. Glutamate in schizophrenia: clinical and research implications. Schizophr Res 1997;27:157-68.
74. Grace AA. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 1991;41:1-24.
75. Huntley GW, Vickers JC, Morrison JH. Cellular and synaptic localization of NMDA and non-NMDA receptor subunits in neocortex: organizational features related to cortical circuitry, function and disease. Trends Neurosci 1994;17:536-43.
76. Goff DC, Coyle JT. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 2001;158:1367-77.
77. Deakin JF, Slater P, Simpson MD, Gilchrist AC, Skan WJ, Royston MC, Reynolds GP, Cross AJ. Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia. J Neurochem 1989;52:1781-6.
78. Nishikawa T, Takashima M, Toru M. Increased [3H]kainic acid binding in the prefrontal cortex in schizophrenia. Neurosci Lett 1983;40:245-50.
79. Toru M, Watanabe S, Shibuya H, Nishikawa T, Noda K, Mitsushio H, et al. Neurotransmitters, receptors and neuropeptides in post-mortem brains of chronic schizophrenic patients. Acta Psychiatr Scand 1988;78:121-37.
80. Harrison PJ, McLaughlin D, Kerwin RW. Decreased hippocampal expression of a glutamate receptor gene in schizophrenia. Lancet 1991;337:450-2.
81. Humphries C, Mortimer A, Hirsch S, de Belleroche J. NMDA receptor mRNA correlation with antemortem cognitive impairment in schizophrenia. Neuroreport 1996;7:2051-55.
82. Kristensen JD, Svensson B, Gordh T. The NMDA-receptor antagonist CPP abolishes neurogenic 'wind-up pain' after intrathecal administration in humans. Pain 1992;51:249-53.
83. Abi-Saab WM, D'Souza DC, Madonick SH, Krystal JH. Targeting the glutamate system. Current Issues in the Psychopharmacology of Schizophrenia. Breier A, Tran PV, Herrera JM, Tollefson GD and Bymaster FP, Eds. (Lippincott, Williams & Wilkins Healthcare, Philadelphia), pp. 304-332 (2001).
84. Mohn AR, Gainetdinov RR, Caron MG, Koller BH. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 1999;98:427-36.
85. Coyle JT. The glutamatergic dysfunction hypothesis for schizophrenia. Harv Rev Psychiatry 1996;3:241-53.
86. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991;148:1301-08.
87. Jentsch JD, Roth RH. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacol 1999;20:201-25.
88. Duncan GE, Miyamoto S, Gu H, Lieberman JA, Koller BH, Snouwaert JN. Alterations in regional brain metabolism in genetic and pharmacological models of reduced NMDA receptor function. Brain Res 2002;951:166-76.
89. 1A dopamine receptors. Brain Res 2001;894:167-80.
90. Vasiliadis H, Elie R, Dewar KM. Interaction between dopamine and glutamate receptors following treatment with NMDA receptor antagonists. Eur J Pharmacol 1999;386:155-63.
91. Zheng P, Zhang XX, Bunney BS, Shi WX. Opposite modulation of cortical N -methyl-D -aspartate receptor-mediated responses by low and high concentrations of dopamine. Neuroscience 1999;91:527-35.
92. Breier A, Adler CM, Weisenfeld N, Su TP, Elman I, Picken L, Malhortra AK, Pickar D. Effects of NMDA antagonism on striatal dopamine release in healthy subjects: application of a novel PET approach. Synapse 1998;29:142-7.
93. 11 C]-raclopride PET study of a model psychosis in humans. J Psychiatr Res 2000;34:35-43.
94. 2 receptors: implications for models of schizophrenia. Mol Psychiatry 2002;7:837-44.
95. Moghaddam B, Adams B, Verman A, Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 1997;17:2921-27.
96. Ohnuma T, Augood SJ, Arai H, McKenna PJ, Emson PC. Expression of the human excitatory amino acid transporter 2 and metabotropic glutamate receptors 3 and 5 in the prefrontal cortex from normal individuals and patients with schizophrenia. Mol Brain Res 1998;56:207-17.
97. McCullumsmith RE, Meador-Woodruff JH. Striatal excitatory amino acid transporter transcript expression in schizophrenia, bipolar disorder and major depressive disorder. Neuropsychopharmacol 2002;26:368-75.
98. Heresco-Levy U: Amino acid transmitter systems, in Biological Psychiatry. Edited by D'haenen H, den Boer JA, Westenberg M, Willner P. London, John Wiley & Sons, 2002, pp 587-600.
99. Hashimoto K, Fukushima T, Shimizu E, Komatsu N, Watanabe H, Shinoda N, Nakazato M, Kumakiri C, Okada S, Hasegawa H, Imai K, Iyo M: Decreased serum levels of D-serine in patients with schizophrenia. Arch Gen Psychiatry 2003;60:572-6.
100. Guy Neeman, Monica Blanaru, Boaz Bloch, Ilana Kremer, Marina Ermilov, Daniel C. Javitt, Uriel Heresco-Levy. Relation of Plasma Glycine, Serine and Homocysteine Levels to Schizophrenia Symptoms and Medication Type. Am J Psychiatry 2005;162:1738-40.
101. Sumiyoshi T, Anil Elif A, Yin D, Jayathialke K, Lee M, Meltzer HY: Plasma, glycine and serine levels in schizophrenia compared to normal controls and major depression: relation to negative symptoms. Int J Neuropsychopharmacol 2004;7:1-8.
102. Lipton SA, Kim W, Choi Y, Kumar S, D'Emilia DM, Rayadu PV, Arnelle DR, Stamler JS: Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor. Proc Natl Acad Sci USA 1997;94:5923-8.
103. Rosenquist TM, Schneider AM, Monaghan DT: N-Methyl-Daspartate receptor agonists modulate homocysteine-induced developmental abnormalities. FASEB J 1999;13:1523-31.
104. Friedman A, Kaufer D, Shemer J, Hendler I, Soreq H, Tur-Kaspa I: Pyridostigmine brain penetration under stress enhances neuronal excitability and induces immediate transcriptional response. Nat Med 1996;2:1382-5.
105. Kruman II, Culmsee C, Chan SL, Kruman Y, Guo Z, Penix L, Mattson MP. Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity. J Neurosci 2000;20:6920-6.
106. Pollin W, Cardon P, Kety S. Effect of amino acid feedings in schizophrenic patients treated with iproniazid. Science 1961;133:104-5.
107. Brown AS, Susser ES. Homocysteine and schizophrenia: from prenatal to adult life. Review article. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:1175-80.
108. Graham I. Homocysteine Metabolism: From Basic Science to Clinical Medicine. Boston, Mass: Kluwer Academic Publishers; 1997.
109. Lewis CA, Pancharuniti N, Sauberlich HE. Plasma folate adequacy as determined by homocysteine level. Ann N Y Acad Sci 1992;669:360-2.
110. McPartlin J, Halligan A, Scott JM, Darling M, Weir DG. Accelerated folate breakdown in pregnancy. Lancet 1993;341:148-9.
111. Brown AS, Bottiglieri T, Schaefer CA, Quesenberry CP Jr, Liu L, Bresnahan M, Susser ES. Elevated prenatal homocysteine levels as a risk factor for schizophrenia. Arch Gen Psychiatry 2007;64:31-9.
112. Coyle JT. The GABA-glutamate connection in schizophrenia: which is the proximate cause? Biochem Pharmacol 2004;68:1507-14.
113. Guidotti A, Auta J, Davis JM, Dong E, Grayson DR, Veldic M, Zhang X, Costa E. GABAergic dysfunction in schizophrenia: new treatment strategies on the horizon. Psychopharmacology (Berl) 2005;180:191-205.
114. Lewis DA, Hashimoto T, Volk DW. Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci 2005;6:312-24.
115. Benes FM, Berretta S. GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder. Neuropsychopharmacol 2001;25:1-27.
116. Hashimoto T, Volk DW, Eggan SM, Mirnics K, Pierri JN, Sun Z, Sampson AR, Lewis DA. Gene expression deficits in a subclass of GABA neurons in the prefrontal cortex of subjects with schizophrenia. J Neurosci 2003;23:6315-26.
117. Buzsaki G, Draguhn A. Neuronal oscillations in cortical networks. Science 2004;304:1926-9.
118. Howard MW, Rizzuto DS, Caplan JB, Madsen JR, Lisman J, Aschenbrenner-Scheibe R, Schulze-Bonhage A, Kahana MJ. Gamma oscillations correlate with working memory load in humans. Cereb Cortex 2003;13:1369-74.
119. Spencer KM, Nestor PG, Niznikiewicz MA, Salisbury DF, Shenton ME, McCarley RW. Abnormal neural synchrony in schizophrenia. J Neurosci 2003;23:7407-11.
120. Spencer KM, Nestor PG, Perlmutter R, Niznikiewicz MA, Klump MC, Frumin M, Shenton ME, McCarley RW. Neural synchrony indexes disordered perception and cognition in schizophrenia. Proc Natl Acad Sci USA 2004;101:17288-93.
121. Lewis DA, Volk DW, Hashimoto T. Selective alterations in prefrontal cortical GABA neurotransmission in schizophrenia: a novel target for the treatment of working memory dysfunction. Psychopharmacology (Berl) 2004;174:143-50.
122. Curran T, D'Arcangelo G. Role of reelin in the control of brain development. Brain Res Brain Res Rev 1998;26:285-94.
123. Impagnatiello F, Guidotti AR, Pesold C, Dwivedi Y, Caruncho H, Pisu MG, et al. A decrease of reelin expression as a putative vulnerability factor in schizophrenia. Proc Natl Acad Sci USA 1998;95:15718-23.
124. Benes FM. Model generation and testing to probe neural circuitry in the cingulate cortex of postmortem schizophrenic brain. Schizophr Bull 1998;24:219-30.
125. Guidotti A, Auta J, Davis JM, Di-Giorgi-Gerevini V, Dwivedi Y, Grayson DR, et al. Decrease in reelin and glutamic acid decarboxylase 67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain study. Arch Gen Psychiatry 2000;57:1061-9.
126. Woo TU, Whitehead RE, Melchitzky DS, Lewis DA. A subclass of prefrontal ?-aminobutyric acid axon terminals are selectively altered in schizophrenia. Proc Natl Acad Sci USA 1998;95:5341-6.
127. Hyde TM, Crook JM. Cholinergic systems and schizophrenia: primary pathology or epiphenomena? J Chem Neuroanat 2001;22:53-63.
128. Kozak R, Martinez V, Young D, Brown H, Bruno JP, Sarter M. Toward a neuro-cognitive animal model of the cognitive symptoms of schizophrenia: disruption of cortical cholinergic neurotransmission following repeated amphetamine exposure in attentional task-performing, but not non-performing, rats. Neuropsychopharmacol 2007;32:2074-86.
129. Bodick NC, Offen WW, Levey AI, Cutler NR, Gauthier SG, Satlin A, et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol 1997;54:465-73.
130. Bymaster FP. Possible role of muscarinic receptor agonists as therapeutic agents for psychosis. Current Issues in the Psychopharmacology of Schizophrenia, Breier A, Tran PV, Herrera JM, Tollefson GD, Bymaster FP, Eds. (Lippincott, Williams & Wilkins Healthcare, Philadelphia), pp. 333-348 (2001).
131. Perry KW, Nisenbauma LK, Georgea CA, Shannona HE, Feldera CC, Bymaster FP. The muscarinic agonist xanomeline has antipsychotic-like activity in animals and in man. Schizophr Res 1999;36:117-8.
132. Svensson T. NE uptake inhibition: implications for brain dopaminergic functioning and antipsychotic drug action. Program and abstracts of the XXIIIrd Congress of the Collegium Internationale Neuro-Psychopharmacologicum; June 23-27, 2002; Montreal, Canada. Abstract S.07.5.
133. Grenhoff J, Nisell M, Ferre S, Aston-Jones G, Svensson TH. Noradrenergic modulation of midbrain dopamine cell firing elicited by stimulation of the locus coeruleus in the rat. J Neural Transm Gen Sect 1993;93:11-25.
134. Hertel P, Fagerquist MV, Svensson TH. Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by alpha2 adrenoceptor blockade. Science 1999;286:105-7.
135. Litman RE, Su T-P, Potter WZ, Hong WW, Pickar D. Idazoxan and response to typical neuroleptics in treatment-resistant schizophrenia: comparison with the atypical neuroleptic, clozapine. Br J Psychiatry 1996;168:571-9.
136. Hertel P, Nomikos GG, Svensson TH. The antipsychotic drug risperidone interacts with auto- and hetero-receptors regulating serotonin output in the rat frontal cortex. Neuropharmacol 1999;38:1175-84.
137. Ballmaier M, Zoli M, Mazzoncini R, Gennarelli M, Spano PR. Combined alpha2-adrenergic/D-sub-2 dopamine receptor blockade fails to reproduce the ability of clozapine to reverse phencyclidine-induced deficits in prepulse inhibition of startle. Psychopharmacol 2001;159:105-10.
138. Stein L, Wise CD. Possible etiology of schizophrenia: progressive damage to the noradrenergic reward system by 6-hydroxydopamine. Science 1971;171:1032-6.
139. Kim YH, Shin JC. Neuropeptides in clinical psychiatric research-endorphins and cholecystokinins. J Korean Soc Biol Psychiatry 1998;5:34-45.
140. Binder EB, Kinkead B, Owens MJ, Nemeroff CB. The role of neurotensin in the pathophysiology of schizophrenia and the mechanism of action of antipsychotic drugs. Biol Psychiatry 2001;50:856-72.
141. Coyle J. The nagging question of the function of N- acetylaspartylglutamate. Neurobiol Dis 1997;4:231-8.
142. Kegles L, Humaran TJ, Mann JJ. In vivo neurochemistry of brain in schizophrenia as revealed by magnetic resonance spectroscopy. Biol Psychiatry 1998;44:382-8.
143. Neale JH, Bzdega T, Wroblewska B. N-Acetylaspartylglutamate: the most abundant peptide neurotransmitter in the mammalian central nervous system. J Neurochem 2000;75:443-52.
144. Nudmamud S, Reynolds LM, Reynolds GP. N-Acetylaspartate and N-Acetylaspartylglutamate deficits in superior temporal cortex in schizophrenia and bipolar disorder: a postmortem study. Biol Psychiatry 2003;53:1138-41.
145. Bertolino A, Callicott JH, Elman I, Mattay VS, Tedeschi G, Frank JA, Breier A, Weinberger DR. Regionally specific neuronal pathology in untreated patients with schizophrenia: a proton magnetic resonance spectroscopic imaging study. Biol Psychiatry 1998;43:641-8.
146. Yurgelun-Todd DA, Renshaw PF, Grubex SA, Ed M, Waternaux C, Cohen BM. Proton magnetic resonance spectroscopy of the temporal lobes in schizophrenics and normal controls. Schizophr Res 1996;19:55-9.
147. Morris HM, Hashimoto T, Lewis DA. Alterations in somatostatin mRNA expression in the dorsolateral prefrontal cortex of subjects with schizophrenia or schizoaffective disorder. Cereb Cortex 2008;18:1575-87.
148. Kasckow J, Nemeroff CB. The neurobiology of neurotensin: focus on neurotensin-dopamine interactions. Regul Pept 1991;36:153-64.
149. Kinkead B, Nemeroff CB. Neurotensin, schizophrenia and antipsychotic drug action. Int Rev Neurobiol 2004;59:327-49.
150. Cáceda R, Kinkead B, Nemeroff CB. Do neurotensin receptor agonists represent a novel class of antipsychotic drugs? Semin Clin Neuropsychiatry 2003;8:94-108.
151. Cáceda R, Kinkead B, Owens MJ, Nemeroff CB. Virally mediated increased neurotensin 1 receptor in the nucleus accumbens decreases behavioral effects of mesolimbic system activation. J Neurosci 2005;25:11748-56.
152. Hernando F, Fuentes JA, Fournié-Zaluski MC, Roques BP, Ruiz-Gayo M. Antidepressant-like effect of CCKb receptor antagonist: involvement of the opioid system. Eur J Pharmacol 1996;318:221-9.
153. Sedvall G, Farde L. Chemical brain anatomy in schizophrenia. Lancet 1995;346:743-9.
154. Wei J, Hemmings GP. The CCK-A receptor gene possibly associated with auditory hallucinations in schizophrenia. Eur Psychiatry 1999;14:67-70.
155. Miller C, Kirchman R, Troger J, Savia A, Fleischhacker WW, Fischer-Colbrie R, Benzer A, Winkler H. CSF of neuroleptic-naive first-episode schizophrenic patients: levels of biogenic amines, substance P, and peptides derived from chromogranin A (GE-25) and secretogranin II (secretoneurin). Biol Psychiatry 1996;39:911-8.
156. Bachus SE, Hyde TM, Herman MM, Egan MF, Kleinman JE. Abnormal cholecystokinin mRNA levels in entorhinal cortex of schizophrenics. J Psychiatr Res 1997;31:233-56.
157. Goldman MB, Robertson GL, Luchins DJ, Hedeker D, Pandey GN. Psychotic exacerbations and enhanced vasopressin secretion in schizophrenic patients with hyponatremia and polydipsia. Arch Gen Psychiatry 1997;54:445-9.
158. Womelduff JC. Neurohormones, schizophrenia and pain: an endocrine-based review. J Amer Chiropr Assoc 1999;36:28-31.
159. Walker EF, Diforio D. Schizophrenia: a neural diathesis-stress model. Psychol Rev 1997;104:667-85.
160. Marx CE, Lieberman JA. Psychoneuroendocrinology of schizophrenia. Psychiatr Clin North Am 1998;21:413-34.
161. Sharma RP, Pandey GN, Janicak PG, Peterson J, Comaty JE, Davis JM. The effect of diagnosis and age on the DST: a metaanalytic approach. Biol Psychiatry 1988;24:555-68.
162. Yeragani VK. The incidence of abnormal dexamethasone suppression in schizophrenia: a review and a meta-analytic comparison with the incidence in normal controls. Can J Psychiatry 1990;35:128-32.
163. Coryell W, Tsuang D. Hypothalamic-pituitary-adrenal axis hyperactivity and psychosis: recovery during an 8-year follow-up. Am J Psychiatry 1992;149:1033-9.
164. Jansen LM, Gispen-de Wied CC, Gademan PJ, De Jonge RC, van der Linden JA, Kahn RS. Blunted cortisol response to a psychosocial stressor in schizophrenia. Schizophr Res 1998;33:87-94.
165. Kaneda Y, Fujii A, Ohmori T. The hypothalamic-pituitary-adrenal axis in chronic schizophrenic patients long-term treated with neuroleptics. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:935-8.
166. Kaneko M, Yokoyama F, Hoshino Y, Takahagi K, Murata S, Watanabe M, Kumashiro H. Hypothalamic-pituitary-adrenal axis function in chronic schizophrenia: association with clinical features. Neuropsychobiol 1992;25:1-7.
167. Walder DJ, Walker EF, Lewine RJ. Cognitive functioning, cortisol release, and symptom severity in patients with schizophrenia. Biol Psychiatry 2000;48:1121-32.
168. Newcomer JW, Faustman WO, Whiteford HA, Moses Jr JA, Csernansky JG. Symptomatology and cognitive impairment associate independently with post-dexamethasone cortisol concentrations in unmedicated schizophrenic patients. Biol Psychiatry 1991;29:855-64.
169. Tandon R, Mazzara C, DeQuardo J, Craig KA, Meador-Woodruff JH, Goldman , Greden JF. Dexamethasone suppression test in schizophrenia: relationship to symptomatology, ventricular enlargement, and outcome. Biol Psychiatry 1991;29:953-64.
170. Breier A, Davis OR, Buchanan RW, Moricle LA, Munson RC. Effects of metabolic perturbation on plasma homovanillic acid in schizophrenia: relationship to prefrontal cortex volume. Arch Gen Psychiatry 1993;50:541-50.
171. Elman I, Adler CM, Malhotra AK, Bir C, Pickar D, Breier A. Effect of acute metabolic stress on pituitary-adrenal axis activation in patients with schizophrenia. Am J Psychiatry 1998;155:979-81.
172. Hanson DR, Gottesman II. Theories of schizophrenia: a genetic-inflammatory-vascular synthesis. BMC Med Genet 2005;6:7.
173. Saetre P, Emilsson L, Axelsson E, Kreuger J, Lindholm E, Jazin E. Inflammation-related genes up-regulated in schizophrenia brains. BMC Psychiatry 2007;7:46.
174. Chengappa KN, Ganguli R, Yang ZW, Shurin G, Brar JS, Rabin BS. Impaired mitogen (PHA) responsiveness and increased autoantibodies in Caucasian schizophrenic patients with the HLA B8/DR3 phenotype. Biol Psychiatry 1995;37:546-9.
175. Henneberg AE, Horter S, Ruffert S. Increased prevalence of antibrain antibodies in the sera from schizophrenic patients. Schizophr Res 1994;14:15-22.
176. Lin A, Kenis G, Bignotti S, Tura GJ, De Jong R, Bosmans E, Pioli R, Altamura C, Scharpé S, Maes M. The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6. Schizophr Res 1998;32:9-15.
177. Maes M, Bocchio Chiavetto L, Bignotti S, Battisa Tura GJ, Pioli R, Boin F , Kenis G, Bosmans E, De Jongh R, Altamura CA. Increased serum interleukin-8 and interleukin-10 in schizophrenic patients resistant to treatment with neuroleptics and the stimulatory effects of clozapine on serum leukemia inhibitory factor receptor. Schizophr Res 2002;54:281-91.
178. Arolt V, Rothermundt M, Wandinger KP, Kirchner H. Decreased in vitro production of interferon-gamma and interleukin-2 in whole blood of patients with schizophrenia during treatment. Mol Psychiatry 2000;5:150-8.
179. Zhang XY, Zhou DF, Zhang PY, Wu GY, Shen YC. Elevated interleukin-2, interleukin-6 and interleukin-8 serum levels in neuroleptic-free schizophrenia: association with psychopathology. Schizophr Res 2002;57:247-58.
180. Kushner I. The phenomenon of the acute phase response. Ann N Y Acad Sci 1982;389:39-48.
181. Alias AG, Vijayan N, Nair DS, Sukumaran M. Serum ceruloplasmin in schizophrenia: significant increase in acute cases especially in catatonia. Biol Psychiatry 1972;4:231-8.
182. Giner J, Morell M, Osorio C. Serum levels of ceruloplasmin as an index of the clinical evolution in schizophrenic patients. Rev Esp Fisiol 1972;28:39-41.
183. Domino EF, Krause RR, Thiessen MM, Batsakis JG. Blood protein fraction comparisons of normal and schizophrenic patients. Arch Gen Psychiatry 1975;32:717-21.
184. Puzynski S, Kalinowski A. Investigations of some physiobiochemical properties of ceruloplasmin in schizophrenics and in normal subjects. Nature 1966;212:399-400.
185. Morera AL, Henry M, García-Hernández A, Fernandez-López L. Acute phase proteins as biological markers of negative psychopathology in paranoid schizophrenia. Acta Esp Psiquiatr 2007;35:249-52.
186. Yang Y, Wan C, Li H, Zhu H, La Y, Xi Z, Chen Y, Jiang L, Feng G, He L. Altered levels of acute phase proteins in the plasma of patients with schizophrenia. Anal Chem 2006;78:3571-6.
187. Arion D, Unger T, Lewis DA, Levitt P, Mirnics K. Molecular evidence for increased expression of genes related to immune and chaperone function in the prefrontal cortex in schizophrenia. Biol Psychiatry 2007;62:711-21.
188. Wan C, La Y, Zhu H, Yang Y, Jiang L, Chen Y, Feng G, Li H, Sang H, Hao X, Zhang G, He L. Abnormal changes of plasma acute phase proteins in schizophrenia and the relation between schizophrenia and haptoglobin (Hp) gene. Amino Acids 2007;32:101-8.
189. Muller N, Ackenheil M. Psychoneuroimmunology and the cytokine action in the CNS: implications for psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 1998;22:1-33.
190. Kronfol Z, Remick DG. Cytokines and the brain: implications for clinical psychiatry. Am J Psychiatry 2000;157:683-94.
191. Naudin J, Capo C, Giusano B, Mège JC, Azorin JM. A differential role for interleukin-6 and tumor necrosis factor in schizophrenia? Schiz.Res 1997;26:227-33.
192. Cazzullo CL, Sacchetti E, Galluzzo A, Panariello A, Adorni A, Pegoraro M, et al. Cytokine profiles in schizophrenic patients treated with risperidone: a 3-month follow-up study. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:33-9.
193. Na KS, Kima YK. Monocytic, Th1 and Th2 cytokine alterations in the pathophysiology of schizophrenia. Neuropsychobiol 2007;56:55-63.
194. Haddad JJ, Saade NE, Safieh-Garabedian B. Cytokines and neuro-immune-endocrine interactions: a role for the hypothalamic-pituitary- adrenal revolving axis. J Neuroimmunol 2002;133:1-19.
195. Zhang XY, Zhou DF, Cao LY, Wu GY, ShenYC. Cortisol and cytokines in chronic and treatment resistant patients with schizophrenia: association with psychopathology and response to antipsychotics. Neuropsychopharmacol 2005;30:1532-8.
196. Frommberger WH, Bauer J, Haselbauer P, Fräulin A, Riemann D, Berger M. Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: comparison between the acute phase and after remission. Eur Arch Psychiatr Clin Neurosci 1997;247:228-33.
197. Tamam L, Yerdelen D, Ozpoyraz N. Psychosis associated with interferon alfa therapy for chronic hepatitis B. Ann Pharmacother 2003;37:384-7.
198. Zhang XY, Zhou DF, Cao LY, Zhang PY, Wu GY, Shen YC. Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia. J Clin Psychiatry 2004;65:940-7.
199. Muller N, Riedel M, Scheppach C, Brandstatter B, Sokullu S, Krampe K, et al. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry 2002;159:1029-34.
200. Shulman Y, Tibbo PG. Neuroactive steroids in schizophrenia. Can J Psychiatry 2005;50:695-702.
201. Paul SM, Purdy RH. Neuroactive steroids. FASEB J 1992;6:2311-22.
202. Rupprecht R, Holsboer F. Neuroactive steroids: mechanisms of action and neuropsychopharmacological perspectives. Trends Neurosci 1999;22:410-16.
203. Rupprecht R. The neuropsychopharmacological potential of neuroactive steroids. J Psychiar Rest 1997;31:297-314.
204. Rupprecht R, Holsboer F. Neuroactive steroids in neuropsychopharmacology. Int Rev Neurobiol 2001;46:461-77.
205. Follesa P, Concas A, Porcu P, Sanna E, Serra M, Mostallino MC, Purdy RH, Biggio G. Role of allopregnanolone in the regulation of GABA-A receptor plasticity during long-term exposure to and withdrawal from progesterone. Brain Res Brain Res Rev 2001;37:81-90.
206. Twyman RE, Macdonald RL. Neurosteroid regulation of GABA-A receptor single-channel kinetic properties of mouse spinal cord neurons in culture. J Physiol 1992;456:215-45.
207. Shirayama Y, Hashimoto K, Suzuki Y, Higuchi T. Correlation of plasma neurosteroids to the severity of negative symptoms in male patients with schizophrenia. Schizophrenia Res 2002;58:69-74.
208. Marx CE, Trost WT, Shampine LJ, Lieberman JA, Morrow AL, Thakore JH. Neuroactive steroids in schizophrenia: relevance to symptoms and therapeutics. Biol Psychiatry 2004;55 Suppl 8:171.
209. Ritsner M, Maayan R, Gibel A, Strous RD, Modai I, Weizman A. Elevation of the cortisol/dehydroepiandrosterone ratio in schizophrenia patients. Eur Neuropsychopharmacol 2004;14:267-73.
210. Barbaccia MD, Affricano D, Purdy RH, Maciocco E, Spiga F, Biggio G. Clozapine, but not haloperidol, increases brain concentrations of neuroactive steroids in the rat. Neuropsychopharmacol 2001;25:489-97.
211. Ugale RR, Hirani K, Morelli M, Chopde CT. Role of neuroactive steroid allopregnanolone in antipsychotic-like action of olanzapine in rodents. Neuropsychopharmacol 2004;29:1597-609.
212. Strous RD, Maayan R, Lapidus R, Stryjer R, Lustig M, Kotler M, Weizman A. Dehydroepiandrosterone augmentation in the management of negative, depressive, and anxiety symptoms in schizophrenia. Arch Gen Psychiatry 2003;60:133-41.
213. Lidow MS. Calcium signaling dysfunction in schizophrenia: a unifying approach. Brain Res Brain Res Rev 2003;43:70-84.
214. Lara DR. Inhibitory deficit in schizophrenia is not necessarily a GABAergic deficit. Cell Mol Neurobiol 2002;22:239-47.
215. Ghisolfi ES, Prokopiuk AS, Becker J, Ehlers JA, Belmontede-Abreu P, Souza DO, Lara DR. The adenosine antagonist theophylline impairs p50 auditory sensory gating in normal subjects. Neuropsychopharmacol 2002;27:629-37.
216. Nawa H, Takahashi M, Patterson PH. Cytokine and growth factor involvement in schizophrenia: support for the developmental model. Mol Psychiatry 2000;5:594-603.
217. Maynard TM, Sikich L, Lieberman JA, LaMantia AS. Neural development, cell-cell signaling, and the "two-hit" hypothesis of schizophrenia. Schizophr Bull 2001;27:457-76.
218. Glantz LA, Lewis DA. Reduction of synaptophysin immunoreactivity in the prefrontal cortex of subjects with schizophrenia. Arch Gen Psychiatry 1997;54:660-665 & 943-52.
219. Tcherepanov AA, Sokolov BP. Age-related abnormalities in expression of mNAs encoding synapsin 1A, synapsin 1B, and synaptophysin in the temporal lobe of schizophrenics. J Neurosci Res 1997;49:639-44.
220. Vawter MP, Cannon-Spoor HE, Hemperly JJ, Hyde TM, VanderPutten DM, Kleinman JE, Freed WJ. Abnormal expression of cell recognition molecules in schizophrenia. Exp Neurol 1998;149:424-52.
221. Blennow K, Davidsson P, Gottfries CG, Ekman R, Heilig M. Synaptic degeneration in thalamus in schizophrenia. Lancet 1996;348:692-3.
222. Honer WG, Falkai P, Young C, Wang T, Xie J, Bonner J, Hu L, Boulianne GL, Luo Z, Trimble WS. Cingulate cortex synaptic terminal proteins and neural cell adhesion molecule in schizophrenia. Neuroscience 1997;78:99-110.
223. Cotter D, Kerwin R, Doshi B, Martin CS, Everall IP. Alterations in hippocampus non-phosphorylated MAP2 protein expression in schizophrenia. Brain Res 1997;765:238-46.
224. Perrone-Bizzozero NI, Sower AC, Bird ED, Benowitz LI, Ivins KJ, Neve RL. Levels of the growth-associated protein GAP-43 are selectively increased in association cortices in schizophrenia. Proc Nat Acad Sci USA 1996;93:14182-7.
225. Thompson PM, Sower AC, Perrone-Bizzozero NI. Altered levels of the synaptosome associated protein SNAP-25 in schizophrenia. Biol Psychiatry 1998;43:239-43.